
ASCO 2022 Conference Coverage
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1
775 views
June 20, 2022
This video was recorded prior to the FDA approval of teclistamab-cqyv (TECVAYLI) for adult patients ...
read more ↘ with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
↖ read less
read more ↘ with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Myeloma